BeStock  
Stocks › Biotechnology › MLTX

MoonLake Immunotherapeutics MLTX

US equityMarket cap rank #3205Biotechnology
$11.07 +$0.04 (+0.36%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $11.07 0.00%
Open$10.79
Prev close$11.03
Day range$10.73 – $11.31
Volume1.72M
Market cap$942.13M
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$0.00
Operating profit-$79.85M-11.8% YoY
Net profit-$79.55M-12.5% YoY
Diluted EPS-$0.93+15.5% YoY
Free cash flow-$63.40M-42.3% YoY
Operating cash flow-$63.40M

Revenue, last 8 quarters

$0.0Dec '24$0.0Mar '25$0.0Jun '25$0.0Sep '25$0.0Dec '25$0.0Mar '26$0.0Jun '26$0.0Sep '26

Net profit, last 8 quarters

$-46.4MDec '24$-40.6MMar '25$-56.1MJun '25$-70.7MSep '25$-63.0MDec '25$-69.7MMar '26$-61.8MJun '26$-79.5MSep '26

Diluted EPS by quarter

-0.72Dec '24-0.63Mar '25-0.87Jun '25-1.10Sep '25-0.92Dec '25-0.98Mar '26-0.84Jun '26-0.93Sep '26

Free cash flow by quarter

$-48.6MDec '24$-38.2MMar '25$-54.5MJun '25$-44.5MSep '25$-58.8MDec '25$-66.3MMar '26$-55.6MJun '26$-63.4MSep '26

Annual revenue

$0.0FY22$0.0FY23$0.0FY24$0.0FY25

Profitability & balance sheet

Return on equity-81.6%
Return on assets-57.3%
Return on invested capital-63.2%
Current ratio9.13
Liabilities / assets29.4%
Cash & investments$498.46M
Total debt$100.66M
Net cash (debt)$397.81M

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Operating Revenue $0.00 $0.00 $0.00 $0.00 $0.00
Operating Expense $79.85M $61.66M $70.02M $244.83M $65.22M
Selling and Admin Expenses $10.98M $11.44M $15.51M $41.97M $9.21M
-General & Admin Expense $10.98M $11.44M $15.51M $41.97M $9.21M
Research & Development $68.87M $50.22M $54.52M $202.86M $56.01M
Operating Profit -$79.85M -$61.66M -$70.02M -$244.83M -$65.22M
Net Non-Operating Interest Income (Expense) -$2.66M -$2.63M -$2.27M -$7.25M -$1.99M
Non-Operating Interest Expense $2.66M $2.63M $2.27M $7.25M $1.99M
Other Income (Expense) $3.59M $2.58M $3.21M $22.37M $4.44M
Gain on Sale of Security -$212,000.00 -$294,000.00 – – –
Other Non-Operating Income (Expenses) $3.81M $2.87M $3.21M $22.37M $4.37M
Pretax Profit -$78.91M -$61.72M -$69.09M -$229.71M -$62.77M
Tax $631,000.00 $90,000.00 $622,000.00 $611,000.00 $248,000.00
Net Profit -$79.55M -$61.81M -$69.71M -$230.32M -$63.02M
Profit from Continuing Operations -$79.55M -$61.81M -$69.71M -$230.32M -$63.02M
Minority Interests $0.00 $0.00 $0.00 -$3.00M -$591,000.00
Net Income to Parent Company -$79.55M -$61.81M -$69.71M -$227.32M -$62.43M
Net Income to Common Stockholders -$79.55M -$61.81M -$69.71M -$227.32M -$62.43M
Basic EPS -$0.93 -$0.84 -$0.98 -$3.53 -$0.92
Diluted EPS -$0.93 -$0.84 -$0.98 -$3.53 -$0.92

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $540.72M $573.95M $400.37M $424.43M $424.43M
Total Current Assets $533.34M $570.04M $396.64M $421.69M $421.69M
Cash and Cash Equivalents & Short-Term Investments $498.46M $537.03M $357.92M $393.97M $393.97M
-Cash and Cash Equivalents $379.70M $477.91M $298.49M $334.52M $334.52M
-Short Term Investments $118.76M $59.13M $59.43M $59.45M $59.45M
Receivables $8.95M $6.56M $5.76M $4.87M $4.87M
-Other Receivables $8.95M $6.56M $5.76M $4.87M $4.87M
Prepaid Assets $25.93M $26.45M $32.96M $22.86M $22.86M
Total Non-Current Assets $7.37M $3.91M $3.73M $2.74M $2.74M
Net PPE $2.16M $2.57M $2.39M $2.14M $2.14M
-Gross PPE $2.16M $2.57M $2.39M $2.14M $2.14M
Other Non-Current Assets $5.22M $1.34M $1.34M $596,000.00 $596,000.00
Total Liabilities $159.09M $145.75M $146.35M $119.95M $119.95M
Total Current Liabilities $58.43M $45.39M $46.11M $45.48M $45.48M
Payables $14.53M $19.38M $24.78M $30.65M $30.65M
-Accounts Payable $13.85M $17.04M $23.38M $28.43M $28.43M
-Total Tax Payable $682,000.00 $2.35M $1.40M $1.09M $1.09M
Current Accrued Expenses $39.12M $22.15M $18.22M $11.27M $11.27M
Short-Term Debt and Capital Lease Obligation $959,000.00 $1.25M $920,000.00 $1.23M $1.23M
-Current Capital Lease Obligation $959,000.00 $1.25M $920,000.00 $1.23M $1.23M
Total Non-Current Liabilities $100.66M $100.36M $100.24M $74.47M $74.47M
Long Term Debt and Capital Lease Obligation $100.66M $100.29M $99.88M $74.47M $74.47M
-Long Term Debt $100.01M $99.51M $99.02M $74.10M $74.10M
-Long Term Capital Lease Obligation $647,000.00 $772,000.00 $865,000.00 $374,000.00 $374,000.00
Total Equity $381.63M $428.20M $254.02M $304.48M $304.48M
Stockholders' Equity $381.63M $428.20M $254.02M $304.48M $304.48M
Capital Stock $8,000.00 $8,000.00 $7,000.00 $7,000.00 $7,000.00
-Common Stock $8,000.00 $8,000.00 $7,000.00 $7,000.00 $7,000.00
Additional Paid-In Capital $1.05B $1.02B $786.31M $766.78M $766.78M
Retained Earnings -$673.97M -$594.42M -$532.62M -$462.91M -$462.91M
Gains/Losses Not Affecting Retained Earnings $2.29M $630,000.00 $322,000.00 $604,000.00 $604,000.00
Employee Benefits – $74,000.00 $353,000.00 $0.00 $0.00
-Other Payable – – – $1.13M $1.13M
Minority Interests – – – $0.00 $0.00

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow -$63.40M -$55.56M -$66.29M -$196.01M -$58.79M
Net cash flow from continuing operations -$63.40M -$55.56M -$66.29M -$196.01M -$58.79M
Net Income from Continuing Operations -$79.54M -$61.81M -$69.71M -$230.32M -$63.02M
Gain/Loss from Continuing Operations -$4,000.00 $9,000.00 $11,000.00 -$58,000.00 -$31,000.00
Depreciation & Depletion & Amortization $905,000.00 $896,000.00 $845,000.00 $2.62M $751,000.00
Other Non-Cash Items $742,000.00 $19,000.00 $422,000.00 -$1.02M -$92,000.00
Change in Working Capital $11.65M $2.78M -$11.21M $19.88M $6,000.00
-Change in Prepaid Assets $514,000.00 $6.51M -$10.10M $561,000.00 $3.86M
-Change in Payables and Accrued Expense $14.83M -$2.55M $950,000.00 $23.15M -$2.63M
-Change in Other Current Assets -$4.97M $9,000.00 -$779,000.00 -$587,000.00 $1.18M
-Change in Other Current Liabilities -$412,000.00 -$395,000.00 -$389,000.00 -$1.22M -$377,000.00
Net cash flow from investing -$58.76M $322,000.00 $98,000.00 $202.99M -$29.91M
Net Cash Flow from Continuing Investing Activities -$58.76M $322,000.00 $98,000.00 $202.99M -$29.91M
Net PPE Purchase and Sale $0.00 $0.00 $0.00 -$35,000.00 $0.00
Net Investment Purchase and Sale -$58.76M $322,000.00 $98,000.00 $203.03M -$29.91M
Financing Cash Flow $26.97M $234.62M $30.64M $146.00M $72.40M
Net Cash Flow from Continuing Financing Activities $26.97M $234.62M $30.64M $146.00M $72.40M
Net Issuance Payments Of Debt $0.00 $0.00 $24.47M $73.02M $0.00
Net Common Stock Issuance $0.00 $234.07M $6.01M $72.40M $72.40M
Proceeds from Stock Option Exercised $28.47M $551,000.00 $170,000.00 $580,000.00 $0.00
Ending Cash Balance $382.69M $477.91M $298.49M $334.52M $334.52M
Net Change in Cash -$95.20M $179.39M -$35.54M $152.98M -$16.31M
Beginning Cash Balance $477.91M $298.49M $334.52M $180.43M $350.74M
Effect of Exchange Rate Changes -$24,000.00 $29,000.00 -$483,000.00 $1.11M $91,000.00
Free Cash Flow -$63.40M -$55.56M -$66.29M -$196.04M -$58.79M
-Change in Receivables – -$798,000.00 -$894,000.00 -$2.03M -$847,000.00

Discussion

No comments yet — be the first to weigh in on MLTX.

Sign in to join the discussion.

Scroll to Top